Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.72 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.59 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123791 | 1.00 | ADK (0.72) | ADKMETTL3METTL14SLC29A1TP53 | |
| SCHEMBL24687181 | 1.00 | ADK (0.72) | ADKMETTL3METTL14SLC29A1TP53 | |
| SCHEMBL25410585 | 0.92 | ADK (0.60) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL31167393 | 0.92 | ADK (0.60) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL29313461 | 0.91 | ADK (0.60) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL31228160 | 0.91 | ADK (0.60) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL29313467 | 0.86 | ADK (0.53) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL22434979 | 0.85 | ADK (0.52) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL22434980 | 0.85 | ADK (0.52) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL24686959 | 0.84 | ADK (0.51) | ADKSLC29A1TP53ADORA3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-06 | — | — | US | disclosed |
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-11-03 | — | — | US | disclosed |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-11-03 | — | — | US | disclosed |
| US-11400108-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-02 | — | — | US | disclosed |
| CN-109694397-B | Cyclic dinucleotide compounds, preparation method and application thereof | 上海弘翊生物科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-08-05 | — | — | US | disclosed |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-08-05 | — | — | US | disclosed |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-02 | — | — | US | disclosed |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400108-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ADK 1636/4885METTL3 322/4885METTL14 594/4885 |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ADK 1636/4885METTL3 322/4885METTL14 594/4885 |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | ADK 370/4885METTL3 4785/4885METTL14 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.